Eko.Ai Pte Ltd. D/B/A Us2.Ai

Company profile

About Eko.Ai Pte Ltd. D/B/A Us2.Ai

Us2.ai (Eko.Ai Pte Ltd.) is a medical AI company specializing in automated echocardiography analysis. The company's FDA-cleared and CE-marked platform serves as an AI Echo Copilot that transforms cardiac ultrasound workflows by delivering fully automated echo reporting from DICOM upload to structured clinical report in under two minutes, with zero manual clicks required. The platform addresses critical bottlenecks in echo labs where reporting time limits throughput and specialist availability restricts patient access. Us2.ai's technology performs real-time processing of echocardiograms, automatically generating measurements, disease detection, and clinical findings without requiring frame selection or manual annotations. The system integrates seamlessly with existing infrastructure including ultrasound devices, PACS, CVIS, and EMR systems, available in both cloud and on-premise deployment models. The platform covers multiple cardiac conditions including cardiac amyloidosis (featuring first-of-its-kind AI-powered detection), heart failure, aortic stenosis, pulmonary hypertension, and provides advanced capabilities like strain analysis and stress echocardiography. Clinical evidence demonstrates a 70% reduction in reporting time and approximately 75% faster diagnosis time. Us2.ai serves cardiologists, sonographers, hospitals, and clinical trial core labs across 28+ countries with over 500 hospitals and 1 million scans analyzed. The company has published research in leading journals including Nature Communications, The Lancet Digital Health, European Heart Journal, JACC, and Circulation.

Company description · Eko.Ai Pte Ltd. D/B/A Us2.Ai official website